Factor V Leiden (Inherited Thrombophilia)
Table of Contents
- Factor V Leiden Explained
- APC Resistance: The Functional Phenotype
- Prevalence and Genetics
- Thrombosis Risk Stratification
- Factor V Leiden and Oral Contraceptives
- Factor V Leiden and Pregnancy
- Diagnosis and Laboratory Testing
- Treatment and Long-Term Management
- Family Screening and Genetic Counseling
- Living with Factor V Leiden
- Key Research Papers
- Connections
- Featured Videos
Factor V Leiden Explained
Factor V Leiden (FVL) is the most common inherited thrombophilia in people of European (Caucasian) descent — a genetic variant that makes the blood's clotting system overactive and substantially raises the lifetime risk of venous thromboembolism (VTE), the umbrella term for deep-vein thrombosis (DVT) and pulmonary embolism (PE).
The mutation lives in the F5 gene on chromosome 1q24.2. A single nucleotide substitution — c.1691G>A — changes amino acid 506 of coagulation Factor V from arginine to glutamine (p.Arg506Gln, also written R506Q). These are the legacy names; GeneReviews (updated 2024) uses the current nomenclature c.1601G>A (p.Arg534Gln) for the same variant. That one amino-acid swap at position 506 sits exactly at the site where activated protein C (APC) normally cuts and inactivates Factor Va. When APC cannot cleave at R506, Factor Va keeps working indefinitely, thrombin generation continues unchecked, and clots form far more readily than they should.
In plain terms: the mutation breaks the blood's built-in "off switch" for clotting, leaving the coagulation cascade running longer than it should after a clot is initiated. The condition follows an autosomal dominant inheritance pattern, meaning a single mutant copy from one parent is enough to raise clotting risk — though inheriting two copies (homozygous) raises it far more dramatically.
FVL was first described by Bertina and colleagues in 1994 when they identified the molecular basis of APC resistance and named the variant after the Dutch city of Leiden where the research was conducted.
APC Resistance: The Functional Phenotype
The function that FVL disrupts — APC resistance — was actually discovered before the mutation itself. In 1993, Bjorn Dahlback's group in Sweden noticed that plasma from certain thrombosis patients failed to prolong the clotting time when purified activated protein C was added. Normal plasma anticoagulates readily because APC degrades Factor Va (at R506 first, then R306 and R679); resistant plasma did not respond. This functional measurement became the APC resistance ratio test.
The standard test adds exogenous APC to a patient's plasma and measures the ratio of activated partial thromboplastin time (aPTT) with APC versus without. A low ratio (poor prolongation) indicates APC resistance. However, the standard test has significant confounders:
- Oral contraceptive pills (OCP) reduce protein S levels and increase Factor VIII, suppressing the ratio independently of FVL.
- Pregnancy physiologically elevates Factor VIII and reduces free protein S, causing spurious APC resistance.
- Antiphospholipid antibodies can interfere with phospholipid-dependent clotting tests.
- Liver disease reduces synthesis of multiple coagulation factors.
- Acute VTE itself elevates Factor VIII as a reactive protein, falsely reducing the ratio.
The modified (dilute) APC resistance test, which dilutes patient plasma in Factor V-deficient plasma before adding APC, largely eliminates these confounders and is more specific for the FVL mutation. Even so, genetic testing by polymerase chain reaction-based R506Q detection has become the gold standard because it is unambiguous, unaffected by concurrent medications or illness, and can be performed at any time.
Prevalence and Genetics
Factor V Leiden shows a striking population distribution that offers clues to its evolutionary history:
- Caucasians of European descent: heterozygous FVL (one mutant copy) is present in approximately 3–8% of the general population — making it by far the most common single-gene thrombophilia. Homozygous FVL (two mutant copies) affects roughly 0.01–0.02% of Caucasians.
- African populations: a 1995 world survey of 3,380 chromosomes from 24 populations found no factor V Leiden in any of 1,600 chromosomes from Africa, Southeast Asia, Australasia, and the Americas; the allele frequency was 4.4% in 618 Europeans and 0.6% in Asia Minor.
- South and East Asian populations: prevalence is approximately 0.5% or lower; some East Asian populations show near-zero prevalence.
- Indigenous peoples of the Americas, sub-Saharan Africa, and indigenous Australia: FVL is largely or entirely absent, suggesting the mutation arose in a European ancestral population after the major population splits from Africa and before or during the peopling of Europe.
The mutation's high frequency in Europeans — despite its clear thrombotic risk — has led researchers to hypothesize a heterozygote advantage, most plausibly reduced peripartum hemorrhage. Women carrying FVL may have had better survival through childbirth in ancestral environments before surgical obstetrics existed, and this survival advantage was sufficient to offset the thrombotic risk.
Inheritance follows an autosomal dominant pattern. Each child of a heterozygous parent has a 50% chance of inheriting the mutation; both sexes are equally affected. Homozygous individuals have two copies (one from each parent) and face dramatically higher risk than heterozygotes. The second most common inherited thrombophilia, Prothrombin G20210A, acts synergistically with FVL when both are present.
Thrombosis Risk Stratification
Understanding FVL's actual risk numbers is essential — both to avoid unnecessary alarm in the many heterozygotes who will never have a clot, and to ensure appropriate vigilance in those at highest risk.
Population baseline: the annual incidence of VTE in the general population is approximately 1 per 1,000 person-years (roughly 0.1% per year). Over a lifetime, about 1 in 20 people will have a VTE event.
Heterozygous FVL:
- The relative risk of VTE is approximately 3–8 times the population baseline (a 1995 Leiden study measured sevenfold). Against the yearly baseline above, that corresponds to roughly 0.3–0.8% per year — a yearly figure, not a lifetime one.
- GeneReviews (updated 2024) describes heterozygotes as having a slightly increased risk for VTE and notes that many people with the factor V Leiden variant never develop thrombosis.
- The absolute annual risk remains low in the absence of other risk factors, which is why routine anticoagulation for asymptomatic heterozygotes is not recommended.
Homozygous FVL:
- VTE risk is approximately 50–80 times the population baseline.
- In the 1995 Leiden study (471 patients with a first deep-vein thrombosis and 474 controls), homozygous patients had their thrombosis at a much younger age than other patients (31 versus 44 years). The authors estimated that the absolute risk for homozygotes may reach several percentage points per year, so that most homozygous individuals will have at least one thrombotic event in their lifetime.
- Homozygous FVL + additional thrombophilias (e.g., concomitant Prothrombin G20210A) produces the highest-risk phenotype short of severe antithrombin III deficiency.
Compound heterozygosity (one FVL allele + one Prothrombin G20210A allele) carries an intermediate risk between single heterozygous FVL and homozygous FVL.
Key modifying factors that add substantially to baseline FVL risk include: pregnancy and the postpartum period, oral contraceptive use, hormone replacement therapy, prolonged immobilization, major surgery, active malignancy, advanced age, obesity, and smoking. For heterozygotes, it is often the combination of FVL with one or more of these triggers — rather than FVL alone — that precipitates a first VTE event.
Factor V Leiden and Oral Contraceptives
The interaction between FVL and combined oral contraceptive pills (OCPs) is one of the most clinically important pharmacogenetic interactions in medicine. Each factor alone raises VTE risk; together, their effects are strongly synergistic — not merely additive.
- OCP alone (estrogen-containing): approximately 3–4 times the population VTE risk, primarily because estrogen increases circulating levels of Factors VII, VIII, X, and fibrinogen while reducing protein S and increasing APC resistance independently of FVL.
- FVL heterozygous alone: approximately 5–8 times the population VTE risk.
- FVL heterozygous + OCP combined: approximately 30–35 times the population VTE risk — a risk multiplication far exceeding what simple addition of the two individual risks would predict.
These figures come from a 1994 Dutch study comparing 155 premenopausal women aged 15 to 49 who had a deep vein thrombosis with 169 population controls: the pill alone raised the risk 3.8-fold, carrying the mutation 7.9-fold, and both together 34.7-fold.
This synergy occurs because OCP-induced APC resistance stacks directly on top of the constitutive APC resistance from FVL. The net result is near-complete loss of the protein C anticoagulant pathway during OCP use in FVL carriers.
Clinical implications:
- The authors of the 1994 study wrote that when a young woman develops thrombosis, her factor V Leiden status should be considered in counselling about her future method of contraception.
- GeneReviews (updated 2024) states that women with a history of VTE who are heterozygous for factor V Leiden, and homozygous women with or without prior VTE, should avoid estrogen-containing contraception and hormone replacement therapy. The risk with progestogen-only pills or levonorgestrel/copper IUDs is substantially lower.
- Routine thrombophilia screening before prescribing OCPs to all women is not recommended by major guidelines — the 2023 American Society of Hematology guideline makes a strong recommendation against testing the general population before combined oral contraceptives are started — because the absolute VTE incidence remains low even for FVL heterozygotes and mass screening is cost-ineffective. Some clinicians test first when there is a personal or strong family history of VTE before age 50.
- In shared decision-making, the individual woman's VTE history, family history, and preferences shape the contraceptive choice rather than a one-size-fits-all algorithm.
Factor V Leiden and Pregnancy
Pregnancy is itself a profoundly hypercoagulable state — a physiological adaptation to reduce hemorrhage at delivery. Clotting factors I, VII, VIII, X, and XII all rise; protein S falls; fibrinolysis is suppressed. These changes peak in the third trimester and persist into the postpartum period. For women with FVL, pregnancy stacks a second pro-thrombotic burden on top of an already-resistant APC system.
VTE in pregnancy with FVL:
- Heterozygous FVL raises pregnancy-associated VTE risk approximately 7-fold compared with non-carriers.
- The absolute risk in heterozygotes without a personal VTE history is still modest — approximately 0.5–1% per pregnancy — meaning most pregnancies are uncomplicated.
- Homozygous FVL + pregnancy is a high-risk combination. GeneReviews (updated 2024) states that for homozygous women, and for women carrying both factor V Leiden and the prothrombin 20210 variant, preventive anticoagulation before and after birth is suggested to prevent a first clot; for heterozygous women, preventive anticoagulation during pregnancy is not recommended to prevent a first clot.
Obstetric complications beyond VTE: FVL has also been associated with placenta-mediated pregnancy complications, including:
- Recurrent pregnancy loss (particularly second-trimester losses)
- Placental abruption
- Severe preeclampsia and HELLP syndrome
- Fetal growth restriction and small-for-gestational-age neonates
- Stillbirth (association is present but modest)
These complications are thought to arise from microthrombosis in placental intervillous spaces, reducing oxygen and nutrient delivery to the fetus. However, the strength of association varies across studies, and obstetric FVL complications are less robustly established than the VTE associations. A 2011 review puts the increased relative risk of pregnancy loss with factor V Leiden at 2- to 3-fold, "although the probability of a successful pregnancy outcome is high." A 2006 systematic review of 79 studies found that, despite the rise in relative risk, the absolute risk of VTE and adverse pregnancy outcomes remains low, and concluded that universal screening for thrombophilia in pregnancy "cannot be justified clinically."
Low molecular weight heparin (LMWH) in pregnancy: LMWH does not cross the placenta and is the anticoagulant of choice during pregnancy. Whether asymptomatic FVL heterozygotes with no personal VTE history benefit from prophylactic LMWH during pregnancy is genuinely controversial. Most guidelines recommend prophylaxis only for women with a personal history of VTE or very strong family history. LMWH is continued or initiated postpartum (the period of highest absolute risk) for 6 weeks in most FVL-positive women who have had a prior VTE.
Diagnosis and Laboratory Testing
The diagnostic workup for suspected inherited thrombophilia — whether prompted by an unprovoked VTE, recurrent VTE, family history, or a pregnancy complication — involves functional screening followed by genetic confirmation.
Step 1 — Functional APC Resistance Assay:
- Standard or modified (dilute) APC resistance ratio.
- A low ratio indicates APC resistance but does not distinguish FVL from acquired causes.
- Can be falsely normal or falsely abnormal in many clinical settings (see APC Resistance section above).
Step 2 — Genetic Testing (Definitive):
- Polymerase chain reaction-based testing for the R506Q (c.1691G>A; current name c.1601G>A, p.Arg534Gln) variant in the F5 gene.
- Definitively identifies heterozygous vs. homozygous status.
- Unaffected by anticoagulants, pregnancy, or acute illness.
- Can be performed at any time, before or after a VTE event, and regardless of ongoing anticoagulation.
Complete Thrombophilia Panel — additional tests often ordered simultaneously:
- Prothrombin G20210A mutation (second most common inherited thrombophilia)
- Protein C activity (functional assay)
- Protein S — total, free, and functional (free protein S most clinically relevant)
- Antithrombin III (AT-III) activity
- Lupus anticoagulant (two tests on two occasions 12 weeks apart)
- Anticardiolipin immunoglobulin G (IgG) and immunoglobulin M (IgM) antibodies
- Anti-beta-2-glycoprotein-1 immunoglobulin G and immunoglobulin M antibodies
- Homocysteine (fasting)
Critical timing consideration: Protein C, protein S, and antithrombin III are consumed or reduced during acute VTE and are also directly suppressed by anticoagulants (warfarin reduces vitamin-K-dependent proteins C and S; heparin may reduce AT-III). For accurate results, these functional assays are drawn either:
- Before anticoagulation is started (during initial diagnostic workup), or
- At least 3 months after anticoagulation is stopped (when acute-phase effects have resolved).
In contrast, polymerase chain reaction-based genetic tests for FVL and Prothrombin G20210A are unaffected by anticoagulation and can be run at any time.
Treatment and Long-Term Management
Management of FVL depends critically on whether a VTE has occurred, the circumstances of that VTE (provoked vs. unprovoked), the patient's zygosity (heterozygous vs. homozygous), and individual bleeding risk.
Acute VTE treatment:
- Initial anticoagulation with low molecular weight heparin (LMWH) or unfractionated heparin, bridged (if using warfarin) or transitioned directly to a direct oral anticoagulant (DOAC).
- DOACs — particularly apixaban and rivaroxaban — are preferred over warfarin for most patients with FVL-associated VTE. They are oral, do not require international normalized ratio (INR) monitoring, and have predictable pharmacokinetics. Dabigatran and edoxaban require a lead-in period of parenteral anticoagulation.
- Warfarin remains appropriate for patients with antiphospholipid syndrome, severe renal impairment, or specific patient preference.
Duration of anticoagulation — the critical management decision:
- Heterozygous FVL + first PROVOKED VTE (e.g., post-surgical, after prolonged immobilization, during pregnancy): 3–6 months of anticoagulation, same as for non-FVL provoked VTE. The recurrence rate after stopping is not substantially higher than in non-FVL patients with provoked VTE.
- Heterozygous FVL + first UNPROVOKED VTE: extended or indefinite anticoagulation is commonly considered. The annual recurrence risk off anticoagulation is approximately 10–15%. A 1997 Italian cohort of 251 patients found recurrent VTE in 39.7% of the 41 factor V Leiden carriers versus 18.3% of non-carriers over up to eight years (hazard ratio 2.4), while a 2011 review concluded that the mutation has at most a modest effect on recurrence risk after a first VTE.
- Heterozygous FVL + recurrent VTE (two or more events): indefinite anticoagulation is recommended in most guidelines.
- Homozygous FVL + any VTE: indefinite anticoagulation is standard practice given the very high recurrence risk.
Asymptomatic FVL without VTE history:
- Routine anticoagulation is not recommended — the absolute annual VTE risk in heterozygotes is low, and the long-term bleeding risk from indefinite anticoagulation is meaningful.
- GeneReviews notes that a short course of preventive anticoagulation when transient risk factors are present may prevent a first clot in heterozygotes. Situations where targeted short-term prophylaxis is used include major surgery (LMWH perioperatively), prolonged hospitalization or immobility, long-haul air travel (hydration, mobility, compression stockings, and for highest-risk patients, LMWH).
- GeneReviews states that heterozygous women with a history of VTE, and homozygous women with or without prior VTE, should avoid estrogen-containing contraception and postmenopausal hormone replacement therapy (HRT), and that women using short-term HRT for severe menopausal symptoms should avoid oral formulations.
- Education about VTE warning signs and when to seek emergency care is critical.
Monitoring: patients on warfarin require regular international normalized ratio monitoring targeting 2.0–3.0. Patients on DOACs require periodic renal function assessment (especially for rivaroxaban and apixaban, which are renally cleared). Bleeding precautions, drug interactions, and the risks of stopping anticoagulation abruptly are standard parts of counseling for anticoagulated patients.
The American College of Chest Physicians (CHEST) antithrombotic guideline for VTE listed in the research papers below (2016) has since been replaced by its 2021 Second Update of the CHEST Guideline and Expert Panel Report.
Family Screening and Genetic Counseling
Because FVL is inherited, identifying it in one family member raises the question of testing for first-degree relatives. Guidelines on this are nuanced:
Arguments for family screening:
- Identifying FVL in an asymptomatic relative allows targeted counseling about contraception choices, pregnancy management, and situational prophylaxis.
- GeneReviews gives a 50% chance of inheriting the variant for each child of a heterozygous person. A homozygous person carries two copies, so each of their children and both of their parents carry at least one copy.
- A positive result in a young woman who would otherwise have started combined OCPs may prompt a safer contraceptive choice and prevent a VTE.
Arguments for caution:
- Most heterozygous FVL carriers will never have a VTE, so a positive test result can generate significant anxiety without commensurate benefit.
- A positive test may affect life insurance or long-term care insurance eligibility in some jurisdictions.
- Knowledge of FVL carrier status is not uniformly associated with improved clinical outcomes in large population studies.
- Routine population screening is not cost-effective given the low absolute risk in heterozygotes.
GeneReviews states that the indications for testing at-risk family members are unresolved and that, without evidence that early identification reduces illness or death, testing decisions are made individually. The 2023 American Society of Hematology thrombophilia-testing guideline issued 23 recommendations, nearly all based on very low certainty evidence: a strong recommendation against testing the general population before starting combined birth-control pills, conditional recommendations for testing in a few specific situations (such as pregnant women with a family history of high-risk thrombophilia types), and conditional recommendations against testing for all other questions it considered.
Groups often considered for testing: relatives of homozygous probands; relatives of individuals with recurrent VTE or early unprovoked VTE; women of childbearing age who are planning pregnancy or considering hormonal contraception; individuals facing major elective surgery or prolonged immobilization. In these contexts, genetic counseling before and after testing ensures that results are interpreted accurately and do not cause unwarranted harm.
Living with Factor V Leiden
For the majority of heterozygous FVL carriers — particularly those who have not had a VTE — day-to-day life does not require major restrictions. The goal is informed awareness, not fear.
Everyday factors linked to clot risk:
- Physical activity: regular movement is one of the most effective ways to reduce VTE risk. Sedentary behavior — especially prolonged sitting — promotes venous stasis in the leg veins, which is the first of Virchow's triad contributing to deep vein thrombosis.
- Long-haul travel: GeneReviews lists travel among circumstantial risk factors. For flights or drives over 4–6 hours, the measures commonly described are regular walking breaks, staying well hydrated, and graduated compression stockings (knee-length, 15–30 mmHg); for people with prior VTE or additional risk factors, LMWH prophylaxis is sometimes used before travel.
- Body weight: obesity significantly amplifies VTE risk, including in FVL carriers.
- Smoking: smoking promotes endothelial damage, a second component of Virchow's triad.
- Know the warning signs: sudden calf pain, redness, and swelling suggest deep vein thrombosis; sudden shortness of breath, chest pain, or hemoptysis suggest PE. Hospitals treat both as medical emergencies.
- Medical alert: carrying documentation of FVL status ensures that emergency and surgical teams are informed. Many patients wear a medical alert bracelet.
- Medical records: FVL status is relevant to any surgical pre-assessment, obstetric booking, and primary care record.
The psychological burden of an inherited thrombophilia diagnosis is real. Patients often worry about passing the mutation to children, about pregnancy risks, and about the possibility of a life-threatening clot. Access to a hematologist or thrombosis specialist, clear written information, and peer support groups (such as a patient advocacy group for blood clots) can substantially reduce this burden.
Key Research Papers
- Bertina RM, Koeleman BP, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 1994;369(6475):64–67. — Original identification of the Factor V Leiden R506Q mutation as the molecular cause of APC resistance. — PubMed PMID: 8164741
- Dahlback B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C. Proc Natl Acad Sci USA. 1993;90(3):1004–1008. — Discovery of the APC resistance phenotype in thrombophilic families, preceding molecular characterization. — PubMed PMID: 8430067
- Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Eisenberg PR, Miletich JP. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med. 1995;332(14):912–917. — Physicians Health Study data establishing FVL as a risk factor for VTE in a large male cohort. — PubMed PMID: 7877648
- Vandenbroucke JP, Koster T, Briët E, Reitsma PH, Bertina RM, Rosendaal FR. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet. 1994;344(8935):1453–1457. — Landmark paper demonstrating the synergistic 30-fold VTE risk from FVL combined with oral contraceptives. — PubMed PMID: 7968118
- Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood. 1995;85(6):1504–1508. — Quantifies the dramatically elevated VTE risk in homozygous versus heterozygous FVL carriers. — PubMed PMID: 7888671
- Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet. 1995;346(8983):1133–1134. — Population genetic study showing the unique European distribution of FVL and its near-absence in African and Asian populations. — PubMed PMID: 7475606
- Middeldorp S, van Hylckama Vlieg A. Does thrombophilia testing help in the clinical management of patients? Br J Haematol. 2008;143(3):321–335. — Comprehensive critical review of whether thrombophilia testing changes patient outcomes and when it is clinically useful. — PubMed PMID: 18710381
- Simioni P, Prandoni P, Lensing AW, et al. The risk of recurrent venous thromboembolism in patients with an Arg506-->Gln mutation in the gene for factor V (factor V Leiden). N Engl J Med. 1997;336(6):399–403. — Prospective cohort study quantifying recurrent VTE rates in FVL patients off anticoagulation and informing anticoagulation duration decisions. — PubMed PMID: 9010145
- Grody WW, Griffin JH, Taylor AK, Korf BR, Heit JA; ACMG Factor V Leiden Working Group. American College of Medical Genetics consensus statement on factor V Leiden mutation testing. Genet Med. 2001;3(2):139–148. — Evidence-based consensus on who should be tested for FVL and how results should guide management. — PubMed PMID: 11280951
- Robertson L, Wu O, Langhorne P, et al. Thrombophilia in pregnancy: a systematic review. Br J Haematol. 2006;132(2):171–196. — Systematic review quantifying the association between FVL and obstetric complications including recurrent pregnancy loss, abruption, and fetal growth restriction. — PubMed PMID: 16398652
- Kujovich JL. Factor V Leiden thrombophilia. Genet Med. 2011;13(1):1–16. — Comprehensive review article covering genetics, prevalence, pathophysiology, diagnosis, and management of FVL. — PubMed PMID: 21116184
- Kearon C, Akl EA, Ornelas J, et al. Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. Chest. 2016;149(2):315–352. — American College of Chest Physicians guideline providing evidence-based recommendations on anticoagulation duration in thrombophilia including FVL. — PubMed PMID: 26867832
- Pastori D, Menichelli D, Valeriani E, Pignatelli P. Factor V Leiden Thrombophilia. In: Adam MP, Bick S, Mirzaa GM, et al., editors. GeneReviews. Seattle (WA): University of Washington, Seattle; 1999 [updated 2024 May 16]. — PubMed PMID: 20301542
- Middeldorp S, Nieuwlaat R, Baumann Kreuziger L, et al. American Society of Hematology 2023 guidelines for management of venous thromboembolism: thrombophilia testing. Blood Adv. 2023;7(22):7101–7138. — PubMed PMID: 37195076
- Stevens SM, Woller SC, Kreuziger LB, et al. Antithrombotic Therapy for VTE Disease: Second Update of the CHEST Guideline and Expert Panel Report. Chest. 2021;160(6):e545–e608. — PubMed PMID: 34352278